N-PALMITOYLETHANOLAMIDE AND MELATONIN FOR USE IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND OTHER NEUROBEHAVIORAL DISORDERS SIMILARLY ACCOMPANIED BY RESTLESSNESS, IRRITABILITY, SLEEP DISORDERS, AND POTENTIALLY STEREOTYPIES

• Main Authors: RAFFAELLA DELLA VALLE, GABRIELE MARCOLONGO, ANTONIO CALIGNANO, MARIA FEDERICA DELLA VALLE, CLAUDIA CRISTIANO, CHIARA GOMIERO, SALVATORE CUZZOCREA
• Format: Patent
• Language: English; Japanese
• Published: 02.11.2023
• Subjects: ACYCLIC OR CARBOCYCLIC COMPOUNDS; CHEMISTRY; FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES

To provide the use of N-palmitoylethanolamide (PEA) in association with melatonin or natural precursors thereof in the treatment of autism spectrum disorder (ASD) and other neurobehavioral disorders similarly accompanied by restlessness, irritability, sleep disorders, and potentially stereotypies.SOLUTION: In particular, the present invention relates to the use of PEA in association with melatonin in the treatment of ASD, wherein the palmitoylethanolamide is administered in association with melatonin or tryptophan (TRP) or 5-hydroxytriptophan (5H-TRP), wherein the administration is separate, combined, or simultaneous.SELECTED DRAWING: None 【課題】本発明は、自閉症スペクトラム障害(ASD)および同様に落ち着きのなさ、興奮性、睡眠障害、および潜在的な常同症を伴う他の神経行動障害の治療における、メラトニンまたはその天然前駆体と併用したN-パルミトイルエタノールアミド(PEA)の使用に関する。【解決手段】特に、本発明は、ASDの治療におけるメラトニンと併用したPEAの使用に関し、ここで、パルミトイルエタノールアミドは、メラトニン、トリプトファン(TRP)または5-ヒドロキシトリプトファン(5H-TRP)と併用して投与され、ここで、投与は、別々、組み合わせ、または同時である。【選択図】なし